Embryonal carcinoma (EC) cell lines can differentiate in culture into a wide variety of cell types with specialized functions (9, 18) . When injected into normal blastocysts, some of these cultured EC cells can participate in embryogenesis and contribute normal tissues to the developing fetus (22, 23, 27) . Thus, it seems likely that EC cells differentiating in culture make use of normal embryonic developmental signals and that the system may be treated as a reasonable alternative to the embryo for studies concerned with early developmental events (17) . Of particular interest are questions concerning the means by which pluripotent cells become committed to acquire particular differentiated characteristics, such as those of a neuron or a muscle. Our previous studies have demonstrated that cultures of P19 EC cells (21) can be induced to differentiate by cell aggregation in the presence of certain drugs and that the cell types formed depend on the drug used as well as on its concentration. In particular, we have shown that P19 cells treated with high, but nontoxic, doses of retinoic acid (RA) develop into neurons and astrocytes (12) , whereas cells from the same population treated with dimethyl sulfoxide (DMSO) (20) or lower RA concentrations (5) differentiate primarily into mesodermal tissues, including muscle. Our ability to manipulate the development of these P19 cells should allow us to address experimentally questions of determination of cell fate.
The present experiments concern the further characterization of the muscle differentiation observed in these cultures. Although muscle is not the only cell type formed, our initial work concerns this cell type since it is easily recognized by light microscopy of living cultures and since a number of muscle-specific gene products are well characterized and available for the analysis of this cell type.
MATERIALS AND METHODS
Cell lines and culture conditions. Cell cultures were grown in alpha minimal essential medium (26) (GIBCO Laboratories, Grand Island, N.Y.) supplemented with 2.5% fetal calf serum (GIBCO Laboratories) and 7.5% bovine serum (Canadian Veterinary Supplies, Perth, Ontario, Canada). Differentiation experiments were initiated by subculturing the cells into bacteriologicalgrade petri dishes as previously described (12) . Under these conditions, the cells spontaneously form floating aggregates (19) . The medium was replaced after 2 days, and the aggregates were plated onto tissue culture dishes after 4 days in suspension. In treated cultures, drugs were usually present in the medium only for the first 2 days of suspension culture, after which the aggregates were washed and transferred to fresh medium with no drugs. At various times after plating, aggregates were scored for the presence of morphologically recognizable cell types by using phase-contrast optics.
The cell lines used were P19 and a subclone resistant to 6-thioguanine and ouabain, P19S1801A1 (OlAl), which have both been described (12, 20, 21 and R. M. Gorczynski, manuscript in preparation) was done as described (13) .
The proportion of cells staining with a particular antibody was determined by staining dissociated cells attached to poly-L-lysine cover slips as previously described (5).
CPK assays. Creatine phosphokinase (CPK) isozymes were separated by DEAE-Sephadex ion-exchange column chromatography (15) with 25 mM Trishydrochloride (pH 7.5) containing 50, 100, and 300 mM NaCl used as stepwise elution buffers. Cell extracts and column fractions were assayed for CPK activity by standard spectrophotometric techniques (25) , and protein measurements were done using the modified Lowry procedure of Hartree (11 cle-specific myosin were used in immunofluorescence experiments to confirm the identity of the muscle cells in these cultures. Staining was observed in mononucleate cardiac muscle as well as in multinucleate skeletal muscle cells and unfused skeletal myoblasts (Fig. 3) .
We also tested cell extracts from day 11 DMSO-treated cultures for the presence of the muscle-specific isozyme of CPK, CPK-M (1, 25, 30) . Only a small amount (<5%) of the CPK activity was eluted off DEAE-Sephadex columns at salt concentrations indicative of the CPK-MB heterodimer. All other activity was of the BB form, the form present in nonmuscle tissue and in embryonic muscle cells (1, 25, 30) .
The rate of muscle cell development in DMSO-treated cultures was followed by using morphological and immunofluorescent staining criteria. Beating muscle was evident at day 5, 1 day after the aggregates were plated (Fig. 4a) . Many of the treated aggregates at days 5 or 6 contained areas that were morphologically recognizable as cardiac muscle but which did not start beating until 1 or 2 days later. Skeletal myoblasts appeared later than cardiac muscle and were first observed on day 7. The myoblasts increased in number and began to fuse into myotubes during the following 3 days of the experiment.
The proportion of muscle-myosin-positive cells was determined for parallel cultures in the same experiments (Fig. 4b) . Muscle-myosinpositive cells were first observed in DMSOtreated cultures at day 4, while the aggregates were still in suspension, and increased during the rest of the experiment to 10 to 15% of the cells by day 10. Some of the positive cells were clearly multinucleate towards the end of the experiment, so the number of muscle-myosin- (13, Fig. 5 and 6) .
Effects of other drugs on muscle development. Since DMSO is a potent inducer of murine erythroleukemia (MEL) cells (6, 7), a number of other MEL cell inducers (10, 16) (24) , and OlAl cells were tested for their response to DMSO in medium supplemented only with this delipidized serum. According to Fuchs and Green (8) , this procedure removes all detectable vitamin A from the medium, so it should eliminate the DMSO response completely if the above hypothesis is correct. In three experiments with two different batches of delipidized serum, DMSO remained effective in inducing muscle differentiation, suggesting that f (Fig. 5) except at low RA doses, at which the effect was due to the DMSO itself. In the experiment shown in Fig. 5 , the proportion of aggregates scored with neurons was low because the aggregates were scored on day 11 , when many of the distinctive neural processes had receded, making identification of neurons more difficult.
In P19 cell aggregates treated with high concentrations of RA, the cell size decreased dramatically compared with the untreated controls during the first 6 days of the experiment (13 Figure 6 shows the response of D3 and of the parental lines to DMSO. Both P19 and OlAl responded to DMSO by a decrease in the proportion of aggregates containing EC cells and by an increase in the proportion containing muscle. P19 consistently produced less cardiac and skeletal muscle than OlAl, although DMSO caused the disappearance of EC cells from both cultures with equal efficiency. Cells of the D3 line did not differentiate at any of the DMSO concentrations tested. Thus, DMSO-treated D3 cells did not develop beating muscle (Fig. 6a) or musclemyosin-positive cells, but they remained morphologically undifferentiated (Fig. 6b) , and 95 to 100% were stained with the EC-specific monoclonal antibody AEC3A1-9. D3 cells did not differentiate in the presence of butyrate (1 mM) or 6-thioguanine (180 mM), nor did muscle develop in response to low doses of RA (10-9 to 10-8 M). At higher RA concentrations (10- 
DISCUSSION
The results reported above extend our previous observations (20) (20) in which the drug serves only as a trigger for a series of cellular events culminating in the differentiation of the cell types observed.
The mutant D3 cells do not differentiate under any of the conditions, including treatment with low concentrations of RA, which would normally induce the parental OlAl cells to form muscle. D3 cells do, however, respond to higher concentrations of RA by differentiating into neurons and glial cells. Thus, this cell line may be a mutant specifically blocked in the ability to develop into certain cell types or in the ability to respond to a particular set of developmental signals.
The four chemicals (DMSO, RA, 6-thioguanine, and butyrate) active in inducing OlAl differentiation all show a similar relationship between dose and differentiation: as the dose of drug increases, the proportion of cells remaining as undifferentiated EC decreases, but different dose levels result in the production of different specialized cell types. The pattern of cell types produced over the range of concentrations tested is the same for all of these drugs: cardiac muscle is most abundant at low doses, and higher doses are required for skeletal muscle. Still higher doses of RA induce the abundant formation of neurons and glia (12) . The highest doses of the other three drugs also produced some neurons, but these concentrations approached toxic levels, so the extensive neural differentiation seen with RA was not observed with these drugs.
The similarity of response of OlAl cells to the four inducing drugs reported here, and the block in differentiation in response to these drugs in the RAC65 cell line (13) , suggest that there are some common intracellular effects produced by these chemically unrelated inducing agents. The action of DMSO did not seem to be mediated by serum retinoids because DMSO was effective in inducing differentiation in medium containing lipid-free serum and because DMSO did not potentiate the response of OlAl cell aggregates to high RA doses. DMSO has effects on a large number of other biological systems and has been extensively studied as an inducer of differentiation of MEL cells (6, 7) . Recent evidence with the MEL cells suggests that a rise in cytoplasmic Ca-is a consequence of DMSO treatment and is a necessary but insufficient condition for MEL differentiation (4, 14, 29 
